{"preliminary_commentary":{"by_channel":{"youtube":18,"podcast":11,"x_thread":8},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT04576156\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"name":"NCT04576156","nct_id":"NCT04576156","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct04576156. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 301+ verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Participants will receive imetelstat sodium at 9.4 mg/kg intravenous (IV) every 21 days (±3 days), until disease progression or unacceptable toxicity, treatment discontinuation or study end.","label":"Imetelstat","type":"EXPERIMENTAL"},{"description":"Participants will receive BAT (investigator-selected non-JAK-inhibitor treatment), until disease progression or unacceptable toxicity, treatment discontinuation or study end.\n\nParticipants on BAT who meet protocol-defined criteria for progressive disease may crossover to receive imetelstat treatment after sponsor's approval.","label":"Best Available Therapy (BAT)","type":"ACTIVE_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2028-06-30","type":"ESTIMATED"},"conditions":["Myelofibrosis"],"enrollment":{"count":327,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Imetelstat","otherNames":["GRN163L"],"type":"DRUG"},{"name":"Best Available Therapy (BAT)","otherNames":[],"type":"DRUG"}],"last_update":"2026-07-08","lead_sponsor":"Geron Corporation","official_title":"A Randomized Open-Label, Phase 3 Study to Evaluate Imetelstat (GRN163L) Versus Best Available Therapy (BAT) in Patients With Intermediate-2 or High-risk Myelofibrosis (MF) Relapsed / Refractory (R/R) to Janus Kinase (JAK) Inhibitor","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2028-06-30","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Overall survival (OS)","timeFrame":"Baseline (Day 1) until End of Study (EOS) (approximately 3 years )]"}],"references":[{"citation":"Mascarenhas J, Harrison CN, Kiladjian JJ, Komrokji RS, Koschmieder S, Vannucchi AM, Berry T, Redding D, Sherman L, Dougherty S, Peng L, Sun L, Huang F, Wan Y, Feller FM, Rizo A, Verstovsek S. Imetelstat in intermediate-2 or high-risk myelofibrosis refractory to JAK inhibitor: IMpactMF phase III study design. Future Oncol. 2022 Jul;18(22):2393-2402. doi: 10.2217/fon-2022-0235. Epub 2022 May 5.","pmid":"35510486","type":"DERIVED"}],"start_date":{"date":"2021-04-12","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment","url":"https://clinicaltrials.gov/study/NCT04576156"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct04576156"}